GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Beilu Pharmaceutical Co Ltd (SZSE:300016) » Definitions » Equity-to-Asset

Beijing Beilu Pharmaceutical Co (SZSE:300016) Equity-to-Asset : 0.58 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Beijing Beilu Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Beijing Beilu Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,663.2 Mil. Beijing Beilu Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥2,869.9 Mil. Therefore, Beijing Beilu Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.58.

The historical rank and industry rank for Beijing Beilu Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

SZSE:300016' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.58   Med: 0.75   Max: 0.94
Current: 0.58

During the past 13 years, the highest Equity to Asset Ratio of Beijing Beilu Pharmaceutical Co was 0.94. The lowest was 0.58. And the median was 0.75.

SZSE:300016's Equity-to-Asset is ranked better than
50.18% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SZSE:300016: 0.58

Beijing Beilu Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Beijing Beilu Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Beilu Pharmaceutical Co Equity-to-Asset Chart

Beijing Beilu Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.61 0.64 0.63 0.59

Beijing Beilu Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.62 0.61 0.59 0.58

Competitive Comparison of Beijing Beilu Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Beilu Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Beilu Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Beilu Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Beijing Beilu Pharmaceutical Co's Equity-to-Asset falls into.



Beijing Beilu Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Beijing Beilu Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1650.617/2819.424
=0.59

Beijing Beilu Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=1663.237/2869.853
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Beilu Pharmaceutical Co  (SZSE:300016) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Beijing Beilu Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Beijing Beilu Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Beilu Pharmaceutical Co (SZSE:300016) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Shuiyuan West Road, Miyun District, Beijing, CHN, 100082
Beijing Beilu Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of pharmaceutical products. The products of the company are contrasted agent series, psychotropic, and hypoglycemic products which include iopamidol injection, iodixanol injection, and reglinide tablets.
Executives
Zong Li Directors, executives
Hong Cheng Jie Director
Duan Xian Zhu Directors, executives
Zhu Zhi Director
Wang Dai Xue Director
Li Hong Directors, executives
Liu Ning Directors, executives
Wu Rui Hua Directors, executives
Wu Jie Executives
Liu Dong Long Supervisors
Hong Wei Directors, executives

Beijing Beilu Pharmaceutical Co (SZSE:300016) Headlines

No Headlines